CREATE MEDIC CO.,LTD.
5187・Standard Market・Precision Instruments
Governance
Company with an Audit and Supervisory Committee. The Board of Directors consists of 7 members (including 4 Audit and Supervisory Committee members and 3 outside directors), and a Nomination and Compensation Committee (with a majority of independent outside directors) has been established. The company has adopted an executive officer system, separating management oversight from business execution. The Board of Directors meets 12 times per year, with all members maintaining a high attendance rate.
Risk Management
The Risk Management Committee oversees and evaluates risks across the group in accordance with the Risk Management Regulations, and reports the results to the Board of Directors. The Committee also identifies and confirms material risks, including sustainability-related risks, with specific countermeasures discussed by the Board of Directors, thereby establishing a comprehensive risk management framework. The Company has also established a Compliance Promotion Committee, an internal whistleblowing contact point, and an internal audit department.
Shareholder Returns
The basic policy is stable and continuous dividends targeting a consolidated payout ratio of 50.0%. For FY2025 (ending December 2025), the annual dividend is ¥45 (interim ¥17, year-end ¥28). For FY2026 (ending December 2026), the annual dividend is forecast at ¥47 (interim ¥20, year-end ¥27). Share buybacks have also been conducted (211,200 shares acquired in March 2026).
Dividend Policy
Dividends are calculated with a target consolidated payout ratio of 50.0%, taking into comprehensive consideration consolidated business performance, future earnings outlook, and internal reserve levels. Dividends are paid twice a year (interim and year-end). For FY2025 (ending December 2025), the annual dividend is ¥45, consisting of an interim dividend of ¥17 and a year-end dividend of ¥28. The forecast for FY2026 (ending December 2026) is an annual dividend of ¥47, consisting of an interim dividend of ¥20 and a year-end dividend of ¥27. There has been no revision from the previous earnings forecast.
ESG
Established the Sustainability Committee in April 2022 to identify materiality issues and manage progress. On the environmental front, formulated a five-year energy efficiency improvement plan in January 2024 and began measuring Scope 1 and 2 emissions. On the social front, established a human rights policy (October 2024), obtained ISO13485 certification at all sites, and participated in medical assistance activities in Vietnam. In terms of human capital, the company has set a target of raising the ratio of female managers to at least 15% by 2030 (long-term target of 30%), and is promoting a Health Management Declaration (September 2023), remote work, and MBA education programs, among other initiatives. The ratio of female managers was 8.1% and the male childcare leave utilization rate was 40.0% (results for the fiscal year under review).
Last updated: March 26, 2026